Study with 3,334 patients validates circulating tumor DNA for genomic sequencing as an alternative to biopsies in mCRPC
The study demonstrated a high correlation between gene mutation changes identified by circulating tumor DNA (ctDNA) and biopsy-based genomic sequencing. In addition, liquid biopsies were better at identifying acquired resistance mechanisms than tissue biopsies.
